Sandro Pignata

Council of Independent Colleges — United States

Medicine · Health Sciences

80h-index34.6kcitations894works7.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(438), PARP inhibition in cancer therapy(175), Endometrial and Cervical Cancer Treatments(155), Cancer Immunotherapy and Biomarkers(129), Renal cell carcinoma treatment(96)

Publications842 total

Cross-platform benchmarking of somatic BRCA1/2 detection: four HRD NGS workflows against the Myriad MyChoice CDx reference assay
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Cross-platform benchmarking of somatic BRCA1/2 detection: four HRD NGS workflows against the Myriad MyChoice CDx reference assay
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Surgical timing in advanced ovarian cancer during the TRUST trial era: A systematic review, meta-analysis and study-level meta-regression of randomized controlled trials
European Journal of Surgical Oncology·2025Open Access
604MO Prognostic value of progression free status at 6 months on overall survival (OS) in platinum resistant ovarian cancer (PROC): Landmark analysis from the GCIG Symptom Benefit Study
Annals of Oncology·2025
663TiP BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)
Annals of Oncology·2025
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective
Frontiers in Immunology·2025Open Access
Supplementary Figure S3 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Figure S1 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Figure S2 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial
npj Precision Oncology·2025Open Access
Multimodal ctDNA profiling identifies fragmentomics and tumor fraction as independent prognostic biomarkers of ovarian cancer survival: the MITO-16a/MANGO-OV2a trial experience
The Journal of Liquid Biopsy·2025Open Access
The impact of body mass index on survival and surgical outcomes in ovarian cancer: insights from the MITO trials
International Journal of Gynecological Cancer·2025
LENVATINIB PLUS PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PARTICIPANTS WITH ADVANCED ENDOMETRIAL CANCER: 5-YEAR OUTCOMES FROM STUDY 309/KEYNOTE-775
International Journal of Gynecological Cancer·2025
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer
Current Oncology·2025· 1 citedOpen Access
Valutazione delle performance nelle reti oncologiche regionali: il modello ValPe.ROC
MECOSAN·2025
Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With Cemiplimab
Journal of Cachexia Sarcopenia and Muscle·2025· 1 citedOpen Access
Physicians’ Controversies Towards Fertility Preservation in Young Patients with Gynecological Cancer: An MITO Survey
Current Oncology·2025Open Access
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer
The Oncologist·2025· 2 citedOpen Access
page 1 of 43Next →

Frequent Co-authors

Nicoletta Colombo(26), Domenica Lorusso(24), Giovanni Scambia(22), Ignace Vergote(19), Isabelle Ray‐Coquard(15), Philipp Harter(14), Jalid Sehouli(12), Jonathan A. Ledermann(12), Susana Banerjee(12), Francesco Raspagliesi(11), Antonio González-Martı́n(10), Mansoor Raza Mirza(10), Éric Pujade-Lauraine(9), Amit M. Oza(9), Ana Oaknin(9), Iain A. McNeish(9), Andreas du Bois(9), David Cibula(9), Patricia Pautier(8), Frédèric Selle(7)